Millennium Research Group Analyst Available to Comment on FDA's Premarket Approval Recommendation of Genzyme Biosurgery's Synvisc Single-Injection Product fo...( WALTHAM Mass. Dec. 12 /- Millennium R...),Health

WALTHAM, Mass., Dec. 12 /PRNewswire/ -- Millennium Research Group (MRG) analyst Deanna Vankessel, author of the recently published Global Markets for Hyaluronic Acid Viscosupplementation 2008 report, is available to offer extensive expertise on the recent FDA premarket approval recommendation of Genzyme Biosurgery's Synvisc single-injection product for osteoarthritis of the knee.

MRG's Deanna Vankessel is available to comment on:

• How this FDA premarket approval recommendation will impact the hyaluronic acid market

• How the recommendation will impact Genzyme Biosurgery and its market share

• How the recommendation will impact patients/consumers

• How the recommendation will potentially impact pricing and technology of other products in the market

MRG's global hyaluronic acid viscosupplementation expertise covers the US, Europe (Austria, France, Germany, Italy, Spain, and the UK), and Japan.

To arrange an interview with Deanna Vankessel, please contact Amy Krohn at 416-364-7776 ext. 101 or akrohn@mrg.net.

About Millennium Research Group

Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResources.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through published reports, ongoing
'/>"/>